Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.
2.
3.
4.

Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.

Zhu S, Liu Y, Wang L, Meng QH.

Nephrol Dial Transplant. 2008 Sep;23(9):2841-6. doi: 10.1093/ndt/gfn159. Epub 2008 Apr 5.

PMID:
18390891
5.
6.
7.

Effects of valsartan and indapamide on plasma cytokines in essential hypertension.

Xie QY, Wang YJ, Sun ZL, Yang TL.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Oct;31(5):629-34.

8.

Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.

Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.

Hypertens Res. 2007 Apr;30(4):307-13.

PMID:
17541209
11.

Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients.

de Champlain J, Karas M, Assouline L, Nadeau R, LeBlanc AR, Dubé B, Larochelle P.

J Clin Hypertens (Greenwich). 2007 Mar;9(3):168-78.

12.

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.

Malacco E, Santonastaso M, Varì NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study.

Clin Ther. 2004 Jun;26(6):855-65. Erratum in: Clin Ther. 2004 Jul;26(7):1185. Clin Ther. 2005 Jan;27(1):142.

PMID:
15262456
13.

Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.

Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.

Clin Ther. 2004 Sep;26(9):1436-45.

PMID:
15531006
14.

Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.

Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD.

J Cardiovasc Pharmacol. 2000 Jun;35(6):937-41.

PMID:
10836730
15.

Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.

Jordan J, Engeli S, Boschmann M, Weidinger G, Luft FC, Sharma AM, Kreuzberg U.

J Hypertens. 2005 Dec;23(12):2313-8.

PMID:
16269974
16.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
17.

Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.

Struck J, Muck P, Trübger D, Handrock R, Weidinger G, Dendorfer A, Dodt C.

J Hypertens. 2002 Jun;20(6):1143-9.

PMID:
12023684
18.

Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan.

Weycker D, Keskinaslan A, Levy DG, Edelsberg J, Kartashov A, Oster G.

Blood Press Suppl. 2008 Dec;2:5-12.

PMID:
19205091
19.

Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.

Fogari R, Zoppi A, Carretta R, Veglio F, Salvetti A; Italian Collaborative Study Group.

J Hypertens. 2002 May;20(5):1007-14.

PMID:
12011663

Supplemental Content

Support Center